FrontThe titration-friendly KSM-66 — 300 mg/cap enables protocol flexibility within one bottle.
Jarrow Formulas KSM-66 is the titration-friendly KSM-66 — real Ixoreal patent at 300 mg/cap (HALF the standard single-cap dose), priced at $18/month. The lower per-cap dose is the feature: it enables 300-900 mg/day flexibility within one bottle, which matters for three specific audiences. Sensitive responders can start at 300 mg AM (week 1-2), gauge sedation and GI tolerance, then ramp to 600 mg via AM/PM split (week 3+) without buying a second bottle.
AM/PM split-dosers running the Lopresti 2019 protocol (300 mg AM + 300 mg PM) get the trial-exact split from one bottle. Multi-supplement stack-builders running 8+ pills/day can incorporate KSM-66 in 300 mg increments rather than the 600 mg single-cap minimum. Backed by Jarrow's 49-year operating history (founded 1977) — one of the longest-running supplement brand histories in the industry, though the company was acquired by New Mountain Capital in 2020 and is no longer family-owned. Eight weeks on the titration protocol, here's the full breakdown.
KSM-66 by Ixoreal Biomed — the Supplement Facts panel prints '300 mg Ashwagandha Extract (Withania somnifera) (Root)' plus the KSM-66 logo on the FRONT panel (not the back). The 5% withanolide standardisation is Ixoreal's published KSM-66 specification — it isn't printed on Jarrow's own Supplement Facts panel, but it's the spec measured in all 24+ published KSM-66 RCTs, and the front-panel logo confirms this is genuine licensed KSM-66. The active extract is IDENTICAL to what's in Double Wood's and Nutricost's bottles — same supplier, same standardisation, same Ixoreal contract. Loses 1 point only because 10% withanolide UHP (Toniiq) is theoretically more concentrated for maxxer-tier upgrades.
KSM-66 is the most-studied ashwagandha extract on earth — 24+ placebo-controlled RCTs across stress, sleep, testosterone, strength, and cognition. Wankhede 2015 (PMID 26609282) and Lopresti 2019 testosterone (PMID 31517876) both used exactly this extract. Lopresti 2019 testosterone specifically split dosing AM/PM in a protocol that 300 mg/cap (Jarrow) hits more naturally than 600 mg/cap (Double Wood). Jarrow's KSM-66 inherits the entire 24+ RCT evidence base by virtue of carrying the patent. Loses 0.5 because Sensoril has stronger cortisol/anxiety case at lower mg doses (Auddy 2008).
Jarrow in-house analytical labs + a 49-year operating history (founded 1977) + batch-level testing — but NO public per-batch COA with consumer lot-lookup the way Double Wood publishes, and no GMP seal or statement appears anywhere on this label (GMP is a company claim we couldn't verify from the bottle). QC documentation is real and available on request via Jarrow customer service. For most buyers, Jarrow's long operating history substitutes for per-batch public lookup; for audit-driven users wanting verifiable proof on their specific bottle's batch, the lack of public lookup is the cost paid for the mid-tier price. Loses 1.5 from Double Wood's 9.0 specifically on the public-COA dimension.
300 mg per capsule, labeled as a 300 mg serving taken twice daily — you reach the 600 mg/day trial dose at 2 caps. Loses 2 points from a perfect 10 because the product's default serving is half the clinical dose, so you self-direct to the trial dose rather than getting it in one labeled serving (Double Wood, by contrast, labels its serving AS the 600 mg trial dose). The upside of the 300 mg granularity: the Lopresti 2019 testosterone trial split-dosed 300 mg AM + 300 mg PM, which Jarrow hits exactly, and it enables titration. Real trade-off, not a defect — the 300 mg increment matches some trial designs (Lopresti split) better than others (Wankhede consolidated).
$18/month at 2 caps/day (to hit 600 mg trial dose) = $0.30 per 300 mg cap = ~$0.02 per mg active withanolide (5% of 300 = 15 mg withanolide/cap, $0.30 ÷ 15 = $0.02/mg). HIGHER per-active-mg than Nutricost KSM-66 ($0.0078/mg) and Double Wood KSM-66 ($0.012/mg) for the same active extract. The titration flexibility costs ~2.5× more per active mg than the budget option. Fair price for the protocol flexibility + Jarrow pedigree, but the math is meaningfully worse than the cheaper KSM-66 competitors at the same patent.
“Contains KSM-66 — the most clinically-validated form of ashwagandha.”
KSM-66 has 24+ published placebo-controlled human RCTs as of 2026 — by a wide margin the most-studied standardised ashwagandha extract. The KSM-66 logo is printed on the front panel, confirming Ixoreal licensing. The 'most clinically-validated' framing is accurate to the trial evidence base.
“Each capsule contains 300 mg of KSM-66 standardised to 5% withanolides.”
300 mg per capsule is printed on the Supplement Facts panel — that part is fully verified. The '5% withanolides' figure is Ixoreal's published KSM-66 specification, not a number printed on Jarrow's own label; we have not seen Jarrow's supplier docs, so we can't independently confirm this specific lot hits 5%. The front-panel KSM-66 logo is the label's own signal that this is genuine licensed extract. The 300 mg per-cap dose is half the Wankhede 2015 single-dose and matches the Lopresti 2019 split-dose AM and PM portions.
“Supports normalized resistance to mental and physical stress*”
This is the label's actual claim (front panel, alongside 'MOOD & STRESS SUPPORT+' and 'ADAPTOGEN' framing) — the word 'cortisol' does not appear anywhere on the bottle. The mechanism behind the claim is well-supported: Chandrasekhar 2012 measured -27.9% morning cortisol at 600 mg/day KSM-66 over 60 days — Jarrow's 2 caps/day protocol hits this dose exactly. Salve 2019 and Lopresti 2019 stress + sleep further substantiate the cortisol-suppression mechanism behind the label's stress-resistance claim at standard KSM-66 doses.
“Supports natural testosterone levels.”
Not a claim Jarrow makes on the label — the bottle's stated claims are stress-resistance, adaptogen, and mood support only. We evaluate testosterone here because it's the primary reason readers search for ashwagandha for testosterone. Verified in stressed, overweight, or resistance-trained populations — Lopresti 2019 testosterone measured +14.7% total T at 600 mg/day KSM-66 (which is Jarrow's 2 caps/day dose); Wankhede 2015 measured +96 ng/dL in resistance-trained men. NOT verified as a generic T-booster claim for already-healthy men with normal cortisol, and not a claim the label itself makes. The mechanism is cortisol-down, so T uplift is conditional on having elevated cortisol to suppress.
“Non-GMO, gluten-free, vegan-friendly.”
All three are verifiable on the label: Non-GMO Project Verified (seal on back panel, also a front-panel check icon), gluten-free (front-panel check icon + 'No wheat, gluten, soybeans...' allergen statement — this is a label claim, not a third-party GF certification mark), and vegan/vegetarian-suitable HPMC capsules (front panel 'VEGAN'). There is no kosher symbol (no OU, K, or Star-K) anywhere on the label or in any of the 10 product photos — an earlier version of this review incorrectly claimed an Orthodox Union kosher certification.
An earlier version of this review said this bottle carries an Orthodox Union kosher certification, that 'Jarrow's supplier docs verify' 5% withanolide standardisation, that the Ixoreal/KSM-66 logo sits on the back panel, and that Jarrow is under 'original-family ownership.' The Supplement Facts panel and the full set of product photos show: no kosher symbol anywhere on the label (front panel lists VEGAN, non-GMO, and gluten-free only); no withanolide percentage printed on the panel at all — 5% is Ixoreal's published KSM-66 specification, not a Jarrow label statement; the KSM-66 logo printed on the FRONT panel, top-right beside the Jarrow wordmark, not the back; and the label itself reads 'Distributed by Jarrow Formulas, Inc., Sherman Oaks, CA' with no ownership claim — Jarrow was acquired by New Mountain Capital in 2020, so it is no longer family-owned, and 1977-to-2026 is 49 years, not 47. We re-read the label on Sep 3, 2026 and revised the text throughout (certifications, standardisation wording, logo placement, manufacturer line, brand-history language) — text only, no score changes.
The most common mistake first-time buyers make with Jarrow KSM-66 is treating the 300 mg/cap as a worse version of a 600 mg cap. It's not worse — it's different. The 300 mg/cap matches Lopresti 2019's split-dosing protocol exactly (300 mg AM + 300 mg PM), enables 300 mg titration from week 1, and accommodates multi-supplement stack-builders who want 300 mg increments. For first-time buyers who just want the dose in one swallow, the single-cap Nutricost 600 mg wins on simplicity. For protocol-driven users who want flexibility within one bottle, Jarrow's 300 mg is the right tool. The mistake is treating dose-per-cap as a quality metric — it's a protocol-fit metric.
Jarrow Formulas was founded in 1977, giving it a 49-year operating history — one of the longest of any consumer supplement brand still selling in the US. The company was acquired by New Mountain Capital in 2020, so it is no longer family-owned (an earlier version of this review incorrectly called it 'original-family ownership'). That said, the operating history still runs across multiple decades of regulatory environments, FDA inspection regimes, and supplement industry shake-outs, and that depth of track record is real regardless of current ownership. Double Wood (founded 2013) and Nutricost (founded 2013) are younger; Toniiq is younger still. For pedigree-first buyers, Jarrow's operating history is unmatched at the trusted-brand tier.
Lopresti 2019 testosterone trial (PMID 31517876) dosed 300 mg KSM-66 AM + 300 mg KSM-66 PM in overweight men 40-70, measuring +14.7% total T over 16 weeks. The split-dose protocol matters because the AM cortisol-suppression window (when cortisol is highest) and the PM sleep-quality window (when KSM-66's mild sedation is a feature) want different timing. Jarrow's 300 mg/cap matches this split exactly, with no pill-splitting workaround. (Double Wood's repackaged 300 mg/cap can run the same split — the genuinely single-cap option is Nutricost's 600 mg, which can't be split without halving a capsule.) Where Jarrow earns its edge for this protocol is the pairing of that 300 mg granularity with a 49-year operating history — the deepest brand track record on the list.
Jarrow KSM-66 at $18/month for 2 caps/day (600 mg total) = $0.02 per mg active withanolide. Nutricost KSM-66 at $14/month for 1 cap/day (600 mg total) = $0.0078 per mg active withanolide — 2.5× cheaper for the same active dose. The premium you pay for Jarrow over Nutricost is essentially the 49-year operating history + the titration flexibility (which Nutricost's single-cap design doesn't offer). For protocol-flexibility buyers, the premium is worth paying. For per-active-mg-optimisers running standard 600 mg consolidated protocols, Nutricost is the smarter math. Don't buy Jarrow for budget reasons — buy it for protocol reasons or for the brand pedigree.
Jarrow's titration flexibility enables a specific diagnostic stack protocol that single-cap bottles can't replicate: Week 1-2 — Jarrow KSM-66 300 mg AM + Double Wood LJ100 Tongkat 200 mg AM (low-dose ashwagandha + standard tongkat). Pull hormone panel at day 14. Week 3-8 — add Jarrow KSM-66 300 mg PM to hit 600 mg/day total. Pull second panel at day 56. The diagnostic value is isolating which lever moves your numbers: if week-1-2 shows free T uplift, tongkat's SHBG displacement is the active mechanism. If week 3-8 adds further uplift, ashwagandha's cortisol-down is contributing additively. Most users can't run this protocol because their ashwagandha bottle doesn't titrate; Jarrow's design enables it.
Jarrow KSM-66 lands at the 'consider' verdict band (8.3) because it's the right pick for a narrow but real audience — and the wrong pick for the broader first-time-buyer audience. The 300 mg/cap is a feature, not a defect: it enables sensitive-responder titration from 300 to 600 mg over weeks 1-2 within one bottle, matches Lopresti 2019's split-dose protocol exactly, and fits multi-supplement stack-builders who want 300 mg increments. Backed by Jarrow's 49-year operating history (founded 1977; acquired by New Mountain Capital in 2020, so no longer family-owned) — one of the longest brand track records on the list. For protocol-driven buyers who value flexibility over single-cap simplicity, this is the right KSM-66. Real Ixoreal patent, real evidence base, real titration capability. The 'consider' (not 'buy') verdict reflects the audience mismatch with first-time buyers. If you're shopping your first KSM-66 bottle and don't have a specific titration or split-dose protocol in mind, the single-cap Nutricost 600 mg ($14/month) is the simplest trial-exact option, and Double Wood ($22/month) is the same dose with a public per-batch COA. If budget is the constraint, Nutricost ($14/month, same active extract, 2.5× cheaper per active mg) wins the math without losing the patent. If you want maximum concentration, Toniiq UHP ($32, 10% withanolides) is the maxxer tier. Jarrow only wins when titration flexibility OR Lopresti 2019 split-dose replication OR its 49-year brand history is the specific job to be done. Upgrade triggers: after the 8-week titration protocol, if you respond well at 600 mg/day and want the simplest single-cap dose for indefinite cycling, move to the single-cap Nutricost 600 mg (or Double Wood for the same dose with a public COA). If you want to push potency for cycle two, move to Toniiq UHP. If you respond well at 300 mg/day low-dose maintenance, stay on Jarrow at 1 cap/day ($9/month) — that's the cheapest legitimate KSM-66 maintenance protocol on the consumer market. If you didn't respond, verify the KSM-66 logo on the front panel (was it real KSM-66?) before concluding non-response; stack with tongkat ali (Double Wood LJ100 200 mg AM, ~$18/month) for the cortisol + SHBG double-lever diagnosis.
Affiliate link — Super Achiever Club earns a small commission at no extra cost to you.
The public-COA alternative at $22/month — same Ixoreal patent at the trial-exact 600 mg dose (a 2-capsule serving) with a per-batch Certificate of Analysis you can look up by lot. The right pick for first-time buyers who want the trial dose with verification.
See it on the list →The budget alternative at $14/month — same Ixoreal patent, same 600 mg trial dose, 2.5× cheaper per active mg than Jarrow. The right pick if titration flexibility isn't your specific need.
See it on the list →The maxxer alternative at $32/month — Toniiq's own 20:1 extract at 10% withanolides (not a KSM-66), single-cap, NSF-grade facility. The right pick once you've validated KSM-66 response and want maximum potency.
See it on the list →600 mg/day KSM-66 split as 300 mg AM + 300 mg PM for 16 weeks in overweight men 40-70 raised total testosterone +14.7% and DHEA-S +18% vs placebo. THE TRIAL THAT JARROW'S 300 MG/CAP MATCHES EXACTLY — Jarrow is uniquely positioned to replicate the Lopresti 2019 split-dose protocol without any pill-splitting workaround.
600 mg/day KSM-66 consolidated AM dose for 8 weeks in resistance-trained men measured serum testosterone +96 ng/dL vs +18 placebo. Demonstrates the consolidated 600 mg/day protocol — Jarrow can hit this dose at 2 caps/day, just with higher pill-count than the single-cap Nutricost.
600 mg/day KSM-66 for 60 days in chronically stressed adults reduced perceived stress -44% and morning cortisol -27.9% vs placebo. The headline cortisol-suppression evidence — Jarrow's 2 caps/day protocol replicates this dose, with the added flexibility of split AM/PM timing for users who want the PM sedation effect on sleep.
240 mg/day KSM-66 for 60 days lowered cortisol -23% and improved sleep + DHEA-S +18% vs placebo. Shows the HPA-axis mechanism is responsive at sub-trial doses — supports Jarrow's low-dose maintenance protocol at 1 cap (300 mg)/day as a valid maintenance dose post-validation.
KSM-66 600 mg/day for 8 weeks in healthy adults improved sleep quality, reduced anxiety, and lowered morning cortisol. Extends the cortisol/stress evidence into the broader 'healthy but stressed' demographic; Jarrow's 2 caps/day protocol replicates this dose.
600 mg/day KSM-66 split AM/PM for 12 weeks in elderly adults improved sleep quality, general well-being, and mental alertness vs placebo. The split-dose elderly evidence — Jarrow's 300 mg/cap matches this split exactly, making it the trial-exact bottle for elderly mixed-gender sleep/well-being protocols.
125-250 mg/day Sensoril for 60 days reduced serum cortisol -24.2% and raised DHEA-S +32%. Cited here as the KSM-66-vs-Sensoril context: Sensoril matches KSM-66's cortisol effect at lower mg doses but lacks the testosterone evidence base that anchors Jarrow's KSM-66 patent.
